USANA Health Sciences, Inc. (NYSE:USNA) Shares Bought by American Century Companies Inc.

American Century Companies Inc. increased its position in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 12.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 233,797 shares of the company's stock after acquiring an additional 25,522 shares during the period. American Century Companies Inc. owned about 1.23% of USANA Health Sciences worth $8,391,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of USNA. Pzena Investment Management LLC increased its stake in USANA Health Sciences by 3.6% during the fourth quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company's stock worth $39,015,000 after purchasing an additional 37,466 shares during the period. Pacer Advisors Inc. increased its stake in USANA Health Sciences by 8.8% during the 4th quarter. Pacer Advisors Inc. now owns 592,001 shares of the company's stock worth $21,247,000 after buying an additional 47,745 shares during the period. State Street Corp increased its stake in USANA Health Sciences by 0.6% during the 3rd quarter. State Street Corp now owns 435,164 shares of the company's stock worth $16,501,000 after buying an additional 2,782 shares during the period. Geode Capital Management LLC lifted its holdings in USANA Health Sciences by 4.5% during the 3rd quarter. Geode Capital Management LLC now owns 297,120 shares of the company's stock worth $11,269,000 after buying an additional 12,898 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its position in USANA Health Sciences by 2.8% in the 4th quarter. Principal Financial Group Inc. now owns 53,603 shares of the company's stock valued at $1,924,000 after buying an additional 1,480 shares during the period. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

USANA Health Sciences Price Performance

Shares of USANA Health Sciences stock traded down $0.38 during trading on Tuesday, hitting $24.32. 231,149 shares of the stock were exchanged, compared to its average volume of 114,184. The stock has a market cap of $459.73 million, a price-to-earnings ratio of 8.59, a price-to-earnings-growth ratio of 0.93 and a beta of 1.00. The firm's 50-day moving average price is $29.77 and its 200 day moving average price is $34.34. USANA Health Sciences, Inc. has a 12-month low of $23.67 and a 12-month high of $49.78.

USANA Health Sciences (NYSE:USNA - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The business had revenue of $213.61 million during the quarter, compared to analysts' expectations of $208.82 million. As a group, research analysts forecast that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on USNA shares. StockNews.com cut USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th. DA Davidson reduced their price target on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, February 27th. Finally, Sidoti downgraded USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 18th.

Insider Buying and Selling at USANA Health Sciences

In other USANA Health Sciences news, CEO Jim Brown sold 5,000 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $29.47, for a total value of $147,350.00. Following the completion of the transaction, the chief executive officer now owns 15,716 shares in the company, valued at $463,150.52. This represents a 24.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Joshua Foukas sold 5,732 shares of USANA Health Sciences stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total value of $186,519.28. The disclosure for this sale can be found here. Insiders have sold 15,920 shares of company stock worth $500,285 over the last three months. Insiders own 0.33% of the company's stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.